Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

Aswan University Hospital

Status: Completed

Conditions: Brain Ischemia

Treatments: Drug: Deferoxamine; Diagnostic Test: Brain Alpha-synuclein; Radiation: Brain computed tomography; Diagnostic Test: Serum Soluble lymphocyte activation gene; Diagnostic Test: Brain lymphocyte activation gene; Diagnostic Test: Serum Iron; Diagnostic Test: Brain Iron; Diagnostic Test: RBCs Alpha-synuclein

Study type: Observational

Funder types: Other

Identifiers

NCT05748587

sLAG-3 in brain ischemia

Details and patient eligibility

About

This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are:

• Is there an association between iron and alpha-synuclein accumulation in ischemic stroke?
• Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?

Enrollment: 48 patients

Sex: All

Ages: 50 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients at the age between 50-70 years.
2. Patients having neurological symptoms of acute ischemic stroke.

Exclusion criteria

1. Patients with acute hemorrhagic stroke.
2. Patients with Parkinson's disease (PD).
3. Patients with dementia, and Alzheimer's disease.
4. Patients with any type of malignancy.
5. Patients with central nervous system infection.

Trial design

48 participants in 5 patient groups

Control

Description:

24 healthy age and sex-matched controls

Treatment:

Diagnostic Test: RBCs Alpha-synuclein

Diagnostic Test: Serum Iron

Diagnostic Test: Serum Soluble lymphocyte activation gene

Radiation: Brain computed tomography

Patients with acute Ischemic stroke

Description:

24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included. Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded.

Treatment:

Diagnostic Test: RBCs Alpha-synuclein

Diagnostic Test: Serum Iron

Diagnostic Test: Serum Soluble lymphocyte activation gene

Radiation: Brain computed tomography

Control rats

Description:

8 rats will be subjected to a Sham operation and will be injected intramuscularly immediately after the operation with an equivalent 0.9% saline solution. After 24 hours they will be sacrificed.

Treatment:

Diagnostic Test: Brain Iron

Diagnostic Test: Brain lymphocyte activation gene

Diagnostic Test: Brain Alpha-synuclein

Rats with ischemic stroke

Description:

8 rats will be subjected to bilateral common carotid artery occlusion (CCAO) for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with an equivalent 0.9% saline solution. They will be sacrificed after 24 hours of reperfusion.

Treatment:

Diagnostic Test: Brain Iron

Diagnostic Test: Brain lymphocyte activation gene

Diagnostic Test: Brain Alpha-synuclein

Rats with ischemic stroke + deferoxamine

Description:

8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion.

Treatment:

Diagnostic Test: Brain Iron

Diagnostic Test: Brain lymphocyte activation gene

Drug: Deferoxamine

Diagnostic Test: Brain Alpha-synuclein